ストックスクリーナーアプリを入手
56.37
0.09%
0.05
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Arturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $65.44 Consensus Target Price from Brokerages - MarketBeat
Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27% - simplywall.st
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - The Columbus Dispatch
Protagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Hennion & Walsh Asset Management Inc. Has $1.26 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
California State Teachers Retirement System Sells 316 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to “Hold” at Wall Street Zen - Defense World
Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga
Exploring Three High Growth Tech Stocks In The US Market - Yahoo Finance
(PTGX) Long Term Investment Analysis - news.stocktradersdaily.com
Protagonist Therapeutics’ (PTGX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech
H.C. Wainwright reaffirms Buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK
BTIG maintains buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK
Protagonist Therapeutics (PTGX) Rating and Price Target Reaffirmed | PTGX Stock News - GuruFocus
Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera - TipRanks
ASCO 2025: Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech
Transcript : Protagonist Therapeutics, Inc.Special Call - marketscreener.com
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide - marketscreener.com
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint - marketscreener.com
Protagonist Therapeutics (PTGX): Promising Phase 3 Results for R - GuruFocus
Protagonist Therapeutics (PTGX): Promising Phase 3 Results for Rusfertide | PTGX Stock News - GuruFocus
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Quantisnow
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded to Sell Rating by Wall Street Zen - Defense World
Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome - MSN
D. E. Shaw & Co. Inc. Sells 21,121 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Bank of America Corp DE Has $5.21 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical advancements - Investing.com India
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Reduced by Ameriprise Financial Inc. - Defense World
BNP Paribas Financial Markets Has $751,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 | PTGX Stock News - GuruFocus
Exclusive: Protagonist Therapeutics CEO Reveals Company Strategy at Major Jefferies Healthcare Conference - Stock Titan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of “Buy” from Analysts - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Given “Buy” Rating at HC Wainwright - Defense World
PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target | PTGX Stock News - GuruFocus
PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target - GuruFocus
First-in-class oral peptide for IL-17 pathway inhibition unveiled - BioWorld MedTech
Protagonist Therapeutics Insiders Sold US$5.1m Of Shares Suggesting Hesitancy - simplywall.st
HC Wainwright Brokers Reduce Earnings Estimates for PTGX - Defense World
Q2 Earnings Estimate for PTGX Issued By HC Wainwright - Defense World
Wedbush Equities Analysts Boost Earnings Estimates for PTGX - Defense World
Protagonist Therapeutics (PTGX) Reveals Promising Phase 3 Trial Results | PTGX Stock News - GuruFocus
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Benzinga
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study - marketscreener.com
J&J posts late-stage data for plaque psoriasis drug (JNJ:NYSE) - Seeking Alpha
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):